Point72 Asset Management
AVBP icon

Point72 Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Point72 Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3M Buy
748,195
+531,535
+245% +$12M 0.02% 885
2025
Q4 		$4.36M Buy
+216,660
New +$4.51M ﹤0.01% 1939
2024
Q2 		– Sell
-28,900
Closed -$516K – 2543
2024
Q1 		$516K Buy
+28,900
New +$583K ﹤0.01% 1641

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management's AVBP Position: Q1 2026 in Review

Point72 Asset Management increased its ArriVent BioPharma (AVBP) stake by 245% in Q1 2026, buying an estimated $12M and bringing the position to 748,195 shares worth $17.3M. The position accounts for 0.02% of the portfolio, ranked #885.

Point72 Asset Management first reported a position in AVBP in Q1 2024 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Point72 Asset Management held 748,195 shares of ArriVent BioPharma worth $17.3M as of Q1 2026.
  • Point72 Asset Management bought 531,535 ArriVent BioPharma shares in Q1 2026, an estimated $12M.
  • ArriVent BioPharma made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #885 holding.
  • Point72 Asset Management first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.